With proliferative advantage of increased signaling feedback between the epithelium and stroma and the additional mutations of genes such as Fgfr3, papillary invasive tumors develop while maintaining Shh expression and low CIS signatures. This evidence concerns the gene FGFR3 and in situ carcinoma.